Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy

Cope, 1997, Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation, J Infect Dis, 176, 1484, 10.1086/514145 Emery, 2000, Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation, J Infect Dis, 182, 1610, 10.1086/317636 Hassan-Walker, 1999, Quantity of human cytomegalovirus (CMV) DNAemia as a risk factor for CMV disease in renal allograft recipients: relationship with donor/recipient CMV serostatus, receipt of augmented methylprednisolone and antithymocyte globulin (ATG), J Med Virol, 58, 182, 10.1002/(SICI)1096-9071(199906)58:2<182::AID-JMV14>3.0.CO;2-Q Mendez, 1998, Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation, Transplantation, 65, 1477, 10.1097/00007890-199806150-00012 Regoes, 2006, Modelling cytomegalovirus replication patterns in the human host: factors important for pathogenesis, Proc Biol Sci, 273, 1961, 10.1098/rspb.2006.3506 Gor, 1998, Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease, Bone Marrow Transplant, 21, 597, 10.1038/sj.bmt.1701139 Humar, 1999, Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients, Transplantation, 68, 1305, 10.1097/00007890-199911150-00015 Emery, 1999, The dynamics of human cytomegalovirus replication in vivo, J Exp Med, 190, 177, 10.1084/jem.190.2.177 Emery, 2000, Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy, Proc Natl Acad Sci USA, 97, 8039, 10.1073/pnas.140123497 Gane, 1997, Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients. The Oral Ganciclovir International Transplantation Study Group, Lancet, 350, 1729, 10.1016/S0140-6736(97)05535-9 Paya, 2004, Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients, Am J Transplant, 4, 611, 10.1111/j.1600-6143.2004.00382.x Winston, 1995, Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients, Lancet, 346, 69, 10.1016/S0140-6736(95)92110-9 Boeckh, 1996, Cytomegalovirus pp65 antigenemia-guided early treatment with ganciclovir versus ganciclovir at engraftment after allogeneic marrow transplantation: a randomized double-blind study, Blood, 88, 4063, 10.1182/blood.V88.10.4063.bloodjournal88104063 Boeckh, 2003, Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity, Blood, 101, 407, 10.1182/blood-2002-03-0993 Ljungman, 2002, Randomized study of valacyclovir as prophylaxis against cytomegalovirus reactivation in recipients of allogeneic bone marrow transplants, Blood, 99, 3050, 10.1182/blood.V99.8.3050 Meyers, 1988, Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation, N Engl J Med, 318, 70, 10.1056/NEJM198801143180202 Prentice, 1994, Impact of long-term acyclovir on cytomegalovirus infection and survival after allogeneic bone marrow transplantation. European Acyclovir for CMV Prophylaxis Study Group, Lancet, 343, 749, 10.1016/S0140-6736(94)91835-X Griffiths, 1998, The effect of valaciclovir on cytomegalovirus viremia and viruria detected by polymerase chain reaction in patients with advanced human immunodeficiency disease, J Infec Dis, 177, 57, 10.1086/513806 Emery, 1999, Quantitative effects of valaciclovir on the replication of cytomegalovirus in patients with advanced human immunodeficiency virus disease: baseline cytomegaloviral load dictates time to disease and survival, J Infec Dis, 180, 695, 10.1086/314936 Ayala, 2006, Valganciclovir is safe and effective as pre-emptive therapy for CMV infection in allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplant, 37, 851, 10.1038/sj.bmt.1705341 Einsele, 1995, Polymerase chain reaction monitoring reduces the incidence of cytomegalovirus disease and the duration and side effects of antiviral therapy after bone marrow transplantation, Blood, 86, 2815, 10.1182/blood.V86.7.2815.2815 Nakamura, 2002, High-dose acyclovir and pre-emptive ganciclovir to prevent cytomegalovirus disease in myeloablative and non-myeloablative allogeneic stem cell transplantation, Bone Marrow Transplant, 30, 235, 10.1038/sj.bmt.1703648 Asberg, 2007, Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients, Am J Transplant, 7, 2106, 10.1111/j.1600-6143.2007.01910.x van der Heiden, 2006, Oral valganciclovir as pre-emptive therapy has similar efficacy on cytomegalovirus DNA load reduction as intravenous ganciclovir in allogeneic stem cell transplantation recipients, Bone Marrow Transplant, 37, 693, 10.1038/sj.bmt.1705311 Gerna, 2005, Rising antigenemia levels may be misleading in pre-emptive therapy of human cytomegalovirus infection in allogeneic hematopoietic stem cell transplant recipients, Haematologica, 90, 526 Nichols, 2001, Rising pp65 antigenemia during preemptive anticytomegalovirus therapy after allogeneic hematopoietic stem cell transplantation: risk factors, correlation with DNA load, and outcomes, Blood, 97, 867, 10.1182/blood.V97.4.867 Humar, 2002, Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease, J Infect Dis, 186, 829, 10.1086/342601 Mattes, 2005, Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir, J Infect Dis, 191, 89, 10.1086/425905 Bowen, 1996, Cytomegalovirus retinitis in AIDS patients: influence of cytomegaloviral load on response to ganciclovir, time to recurrence and survival, AIDS, 10, 1515, 10.1097/00002030-199611000-00009 Spector, 1998, Plasma cytomegalovirus (CMV) DNA load predicts CMV disease and survival in AIDS patients, J Clin Invest, 101, 497, 10.1172/JCI1101 Emery, 2002, Human cytomegalovirus (HCMV) replication dynamics in HCMV-naive and -experienced immunocompromised hosts, J Infect Dis, 185, 1723, 10.1086/340653 Tormo, 2010, Lack of prompt expansion of cytomegalovirus pp65 and IE-1-specific IFNgamma CD8(+) and CD4(+) T cells is associated with rising levels of pp65 antigenemia and DNAemia during pre-emptive therapy in allogeneic hematopoietic stem cell transplant recipients, Bone Marrow Transplant, 45, 543, 10.1038/bmt.2009.172 Grob, 1987, Immune donors can protect marrow-transplant recipients from severe cytomegalovirus infections, Lancet, 1, 774, 10.1016/S0140-6736(87)92800-5 Ljungman, 2006, Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation, Haematologica, 91, 78 Sia, 2000, Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation, J Infect Dis, 181, 717, 10.1086/315242 Mattes, 2004, A randomized, controlled trial comparing ganciclovir to ganciclovir plus foscarnet (each at half dose) for preemptive therapy of cytomegalovirus infection in transplant recipients, J Infect Dis, 189, 1355, 10.1086/383040 Morris, 2003, Pharmacokinetics of alemtuzumab used for in vivo and in vitro T-cell depletion in allogeneic transplantations: relevance for early adoptive immunotherapy and infectious complications, Blood, 102, 4, 10.1182/blood-2002-09-2687 Chakrabarti, 2002, High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution, Blood, 99, 4357, 10.1182/blood.V99.12.4357 Lilleri, 2008, Human cytomegalovirus-specific CD4+ and CD8+ T-cell reconstitution in adult allogeneic hematopoietic stem cell transplant recipients and immune control of viral infection, Haematologica, 93, 248, 10.3324/haematol.11912